Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. Analysis

Analysis

Evaluate

Thumbnail
March 24, 2023

Spotlight – Vertex flexes its dealmaking muscle

The developer has two new collaborations in rare dystrophies, with Entrada and Tevard, but work is early and certain rivals are some way ahead.

March 15, 2023

Europe rues SVB loss as a cornerstone life science supporter

With deeps links to the US likely severed, and HSBC’s risk appetite unknown, what does a future without Silicon Valley Bank look like?

Article image
Vantage logo
March 08, 2023

Spotlight – Seeking target selectivity in achondroplasia

As Bridgebio appears to validate FGFR3 as a target in achondroplasia, who else might follow suit?

Article image
Vantage logo
March 03, 2023

Spotlight – What's next in Nash

The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.

Article image
Vantage logo
February 24, 2023

Spotlight – Cystic fibrosis developers take a deep breath

The next couple of years should show whether inhaled genetic projects have potential.

Article image
Vantage logo
February 22, 2023

US deal watchdog's bark could be worse than its bite

Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?  

Article image
Vantage logo
February 15, 2023

Spotlight – still plenty of hopefuls in lung fibrosis

Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.

Article image
Vantage logo
February 06, 2023

The slow death of the medtech Spac deal

The remarkable thing is that these tie-ups are still occurring, so atrocious is their track record.

Article image
Vantage logo
February 02, 2023

A renewed push into early bladder cancer

Ferring's Adstiladrin has joined Keytruda with a US approval, but it might not be the answer doctors are looking for.

Article image
Vantage logo
January 25, 2023

Immuno-oncology goes subcutaneous

A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.

Article image
Vantage logo
January 05, 2023

The biggest-selling drugs of 2023

Move over Comirnaty: Keytruda takes top spot as its indications broaden and demand for Covid vaccines recedes.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up